Update on anti-phospholipid antibodies in SLE: the Hopkins' Lupus Cohort

被引：61

作者：

Petri, M. ^{[1
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Div Rheumatol, Baltimore, MD 21205 USA

来源：

LUPUS | 2010年 / 19卷 / 04期

关键词：

anti-cardiolipin antibodies; anti-phospholipid syndrome; lupus anticoagulant; VENOUS THROMBOSIS; ENDOTHELIAL-CELLS; ERYTHEMATOSUS; ANTICOAGULANT; RISK;

D O I：

10.1177/0961203309360541

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Anti-phospholipid antibodies are common in patients in the Hopkins' Lupus Cohort: 47% have anti-cardiolipin, 32.5% anti-beta(2)- glycoprotein I and 26% lupus anticoagulant (by dRVVT confirmatory testing). Systemic lupus erythematosus patients with the lupus anticoagulant at baseline have a 50% chance of a deep venous thrombosis/pulmonary embolus in the next 20 years. Anti-phospholipid antibodies differ in their association with thrombosis: the lupus anticoagulant is most strongly associated with arterial and venous thrombosis and is the only anti-phospholipid antibody associated with myocardial infarction. Anti-phospholipid antibodies are not associated with atherosclerosis. Lupus (2010) 19, 419-423.

引用

页码：419 / 423

页数：5

共 13 条

[1] INDUCTION OF ENDOTHELIAL-CELL TISSUE FACTOR ACTIVITY BY SERA FROM PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME - A POSSIBLE MECHANISM OF THROMBOSIS [J].

BRANCH, DW ;

RODGERS, GM .

AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1993, 168 (01) :206-210

[2]

DelPapa N, 1997, AM J REPROD IMMUNOL, V38, P212

[3] COAGULATION SCREEN IS MORE SPECIFIC THAN THE ANTICARDIOLIPIN ANTIBODY ELISA IN DEFINING A THROMBOTIC SUBSET OF LUPUS PATIENTS [J].

DERKSEN, RHWM ;

HASSELAAR, P ;

BLOKZIJL, L ;

MEYLING, FHJG ;

DEGROOT, PG .

ANNALS OF THE RHEUMATIC DISEASES, 1988, 47 (05) :364-371

[4] ANTIPHOSPHOLIPID ANTIBODIES AND VENOUS THROMBOEMBOLISM [J].

GINSBERG, JS ;

WELLS, PS ;

BRILLEDWARDS, P ;

DONOVAN, D ;

MOFFATT, K ;

JOHNSTON, M ;

STEVENS, P ;

HIRSH, J .

BLOOD, 1995, 86 (10) :3685-3691

[5]

Horbach DA, 1996, THROMB HAEMOSTASIS, V76, P916

[6]

Kiani AN, 2008, J RHEUMATOL, V35, P1300

[7]

Maksimowicz-McKinnon K, 2006, J RHEUMATOL, V33, P2458

[8] International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS) [J].

Miyakis, S ;

Lockshin, MD ;

Atsumi, T ;

Branch, DW ;

Brey, RL ;

Cervera, R ;

Derksen, RHWM ;

De Groot, PG ;

Koike, T ;

Meroni, PL ;

Reber, G ;

Shoenfeld, Y ;

Tincani, A ;

Vlachoyiannopoulos, PG ;

Krilis, SA .

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (02) :295-306

[9] THE FREQUENCY OF LUPUS ANTICOAGULANT IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A STUDY OF 60 CONSECUTIVE PATIENTS BY ACTIVATED PARTIAL THROMBOPLASTIN TIME, RUSSELL VIPER VENOM TIME, AND ANTICARDIOLIPIN ANTIBODY LEVEL [J].

PETRI, M ;

RHEINSCHMIDT, M ;

WHITINGOKEEFE, Q ;

HELLMANN, D ;

CORASH, L .

ANNALS OF INTERNAL MEDICINE, 1987, 106 (04) :524-531

[10] ACTIVATION OF CULTURED VASCULAR ENDOTHELIAL-CELLS BY ANTIPHOSPHOLIPID ANTIBODIES [J].

SIMANTOV, R ;

LASALA, JM ;

LO, SK ;

GHARAVI, AE ;

SAMMARITANO, LR ;

SALMON, JE ;

SILVERSTEIN, RL .

JOURNAL OF CLINICAL INVESTIGATION, 1995, 96 (05) :2211-2219

← 1 2 →